Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sanofi said the analysis showed more cases of severe disease could occur following vaccination in patients who had not been previously infected by the dengue virus.
Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints.
On Wednesday, KBR reported that a male employee at Novartis Korea reported to the company that his female boss sexually harassed him in September.
As 2017 comes to a close, 40 drugs have been approved so far, with the record being in 2015, when 46 drugs were approved.
After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported.
A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.
The former Globus engineer took the new job at Stryker earlier this month.
The agreement, whose final terms are still being negotiated, must be approved by a court.
The price of a single pill went up from 16p to 9.22 pounds, even though production costs remained broadly stable during that period, the CMA said.
Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents.